Stacy Markel
CIK: 0001734780
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Nuvation Bio Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 23, 2026NUVB
Nuvation Bio Inc.
Exercise(M)Direct90.4K shares at avg. $1.87$169K - Jun 23, 2026NUVB
Nuvation Bio Inc.
Exercise(M)Direct34.6K shares at avg. $1.74$60K - Jun 23, 2026NUVB
Nuvation Bio Inc.
Sale(S)Direct125K shares at avg. $6.03$753K - Feb 27, 2026NUVB
Nuvation Bio Inc.
Award(A)DirectStock Option (Right to Buy)
748.1K shares- - Jun 18, 2025NUVB
Nuvation Bio Inc.
Purchase(P)Direct10K shares at avg. $1.71$17K - Feb 28, 2025NUVB
Nuvation Bio Inc.
Award(A)DirectStock Option (Right to Buy)
500K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 23, 2026 | NUVB Nuvation Bio Inc. | Exercise(M) | 90,380 | $1.87 | $169,011 | Direct |
| Jun 23, 2026 | NUVB Nuvation Bio Inc. | Exercise(M) | 34,620 | $1.74 | $60,239 | Direct |
| Jun 23, 2026 | NUVB Nuvation Bio Inc. | Sale(S) | 125,000 | $6.03 | $753,188 | Direct |
| Feb 27, 2026 | NUVB Nuvation Bio Inc. | Award(A) Stock Option (Right to Buy) | 748,130 | - | - | Direct |
| Jun 18, 2025 | NUVB Nuvation Bio Inc. | Purchase(P) | 10,000 | $1.71 | $17,100 | Direct |
| Feb 28, 2025 | NUVB Nuvation Bio Inc. | Award(A) Stock Option (Right to Buy) | 500,000 | - | - | Direct |
1-6 of 6 transactions
About Markel Stacy
Markel Stacy (SEC CIK 0001734780) files insider reports with the SEC as CHIEF PEOPLE OFFICER of Nuvation Bio Inc. (NUVB).
Signal8 holds 4 ownership filings by Markel Stacy, all Form 4s, filed between Mar 4, 2025 and Jun 24, 2026. Those filings report 6 transactions, from Feb 28, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Markel Stacy's filings is in NEW YORK, NY.
Recent filings by Markel Stacy
- Jun 23, 2026: Option exercises of NUVB shares (2 lines, Form 4, code M).
- Jun 23, 2026: Open-market sale of NUVB shares (Form 4, code S).
- Feb 27, 2026: Grant or award of NUVB derivative securities (Form 4, code A).
- Jun 18, 2025: Open-market purchase of NUVB shares (Form 4, code P).
- Feb 28, 2025: Grant or award of NUVB derivative securities (Form 4, code A).
Other insiders filing for Nuvation Bio Inc. (NUVB)
- Hattersley Gary, CHIEF SCIENTIFIC OFFICER
- Sauvage Philippe, Chief Financial Officer
- Wentworth Kerry, CHIEF REGULATORY OFFICER
- Mashal Robert, Director
- VERNON W ANTHONY, Director
- FALBERG KATHRYN E, Director